Clive Holmes

List of Publications by Year
in descending order

81 papers	29,207 citations	50276 46 h-index	54911 84 g-index
91 all docs	91 docs citations	91 times ranked	30918 citing authors

#	Article	IF	Citations
1	Neuroinflammation in Alzheimer's disease. Lancet Neurology, The, 2015, 14, 388-405.	10.2	4,129
2	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	21.4	3,741
3	Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics, 2009, 41, 1088-1093.	21.4	2,697
4	Genetic meta-analysis of diagnosed Alzheimerâ€™s disease identifies new risk loci and implicates AÎ², tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	21.4	1,962
5	Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nature Genetics, 2011, 43, 429-435.	21.4	1,708
6	Neuropathology of human Alzheimer disease after immunization with amyloid-Î² peptide: a case report. Nature Medicine, 2003, 9, 448-452.	30.7	1,423
7	Microglia in neurodegenerative disease. Nature Reviews Neurology, 2010, 6, 193-201.	10.1	1,354
8	Long-term effects of AÎ²42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet, The, 2008, 372, 216-223.	13.7	1,333
9	Systemic infections and inflammation affect chronic neurodegeneration. Nature Reviews Immunology, 2007, 7, 161-167.	22.7	887
10	Microglial priming in neurodegenerative disease. Nature Reviews Neurology, 2014, 10, 217-224.	10.1	827
11	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	21.4	783
12	New insights into the genetic etiology of Alzheimerâ€™s disease and related dementias. Nature Genetics, 2022, 54, 412-436.	21.4	700
13	Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease. New England Journal of Medicine, 2012, 366, 893-903.	27.0	626
14	Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurology, The, 2007, 6, 305-313.	10.2	598
15	Sertraline or mirtazapine for depression in dementia (HTA-SADD): a randomised, multicentre, double-blind, placebo-controlled trial. Lancet, The, 2011, 378, 403-411.	13.7	444
16	Rare coding variants in the phospholipase D3 gene confer risk for Alzheimerâ€™s disease. Nature, 2014, 505, 550-554.	27.8	425
17	Common polygenic variation enhances risk prediction for Alzheimerâ€™s disease. Brain, 2015, 138, 3673-3684.	7.6	359
18	Genetic Evidence Implicates the Immune System and Cholesterol Metabolism in the Aetiology of Alzheimer's Disease. PLoS ONE, 2010, 5, e13950.	2.5	347

#	Article	IF	Citations
19	Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. British Journal of Psychiatry, 1999, 174, 45-50.	2.8	329
20	Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nature Genetics, 1999, 21, 71-72.	21.4	260
21	AÎ² Species Removal After AÎ²₄₂Immunization. Journal of Neuropathology and Experimental Neurology, 2006, 65, 1040-1048.	1.7	260
22	Drug repositioning for Alzheimer's disease. Nature Reviews Drug Discovery, 2012, 11, 833-846.	46.4	239
23	Inflammatory components in human Alzheimerâ€™s disease and after active amyloid-Î²42 immunization. Brain, 2013, 136, 2677-2696.	7.6	234
24	Etanercept in Alzheimer disease. Neurology, 2015, 84, 2161-2168.	1.1	203
25	Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology. Journal of Psychopharmacology, 2017, 31, 147-168.	4.0	198
26	Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimer's Research and Therapy, 2010, 2, 1.	6.2	189
27	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.8	173
28	Association between Dementia and Infectious Disease. Alzheimer Disease and Associated Disorders, 2005, 19, 91-94.	1.3	161
29	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	2.5	155
30	Common variants in Alzheimerâ€™s disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	12.8	140
31	Persistent neuropathological effects 14 years following amyloid-Î² immunization in Alzheimerâ€™s disease. Brain, 2019, 142, 2113-2126.	7.6	127
32	Determining the minimum clinically important differences for outcomes in the DOMINO trial. International Journal of Geriatric Psychiatry, 2011, 26, 812-817.	2.7	126
33	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. Lancet Neurology, The, 2015, 14, 1171-1181.	10.2	124
34	Neuropathology after active AÎ²42 immunotherapy: implications for Alzheimerâ€™s disease pathogenesis. Acta Neuropathologica, 2010, 120, 369-384.	7.7	122
35	Targeting innate immunity for neurodegenerative disorders of the central nervous system. Journal of Neurochemistry, 2016, 138, 653-693.	3.9	106
36	Reduction of aggregated Tau in neuronal processes but not in the cell bodies after AÎ²42 immunisation in Alzheimerâ€™s disease. Acta Neuropathologica, 2010, 120, 13-20.	7.7	80

#	Article	IF	Citations
37	Use of Flutemetamol F 18â€“Labeled Positron Emission Tomography and Other Biomarkers to Assess Risk of Clinical Progression in Patients With Amnestic Mild Cognitive Impairment. JAMA Neurology, 2018, 75, 1114.	9.0	75
38	Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age and Ageing, 2003, 32, 200-204.	1.6	71
39	Alzheimerâ€™s disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. Translational Psychiatry, 2019, 9, 154.	4.8	69
40	Systemic inflammation and Alzheimer's disease. Biochemical Society Transactions, 2011, 39, 898-901.	3.4	67
41	Role of Infection in the Pathogenesis of AlzheimerÊ¼s Disease. CNS Drugs, 2009, 23, 993-1002.	5.9	66
42	Depression in Alzheimer's disease: The effect of serotonin receptor gene variation. American Journal of Medical Genetics Part A, 2003, 119B, 40-43.	2.4	58
43	Shared genetic contribution to ischemic stroke and Alzheimer's disease. Annals of Neurology, 2016, 79, 739-747.	5.3	56
44	The Role of Variation at AÎ²PP, PSEN1, PSEN2, and MAPT in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2012, 28, 377-387.	2.6	53
45	Systemic infection modifies the neuroinflammatory response in late stage Alzheimerâ€™s disease. Acta Neuropathologica Communications, 2018, 6, 88.	5.2	52
46	The Locus Coeruleus in Aging and Alzheimerâ€™s Disease: A Postmortem and Brain Imaging Review. Journal of Alzheimer's Disease, 2021, 83, 5-22.	2.6	52
47	Concordant Association of Insulin Degrading Enzyme Gene (IDE) Variants with IDE mRNA, AÂŸ, and Alzheimer's Disease. PLoS ONE, 2010, 5, e8764.	2.5	48
48	Costâ€effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	2.7	48
49	Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age and Ageing, 1998, 27, 181-188.	1.6	44
50	DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease â€“ a multicentre RCT. Trials, 2009, 10, 57.	1.6	44
51	AÎ² immunotherapy for Alzheimerâ€™s disease: effects on apoE and cerebral vasculopathy. Acta Neuropathologica, 2014, 128, 777-789.	7.7	44
52	Cost-effectiveness analyses for mirtazapine and sertraline in dementia: randomised controlled trial. British Journal of Psychiatry, 2013, 202, 121-128.	2.8	43
53	Male Sex Hormones and Systemic Inflammation in Alzheimer Disease. Alzheimer Disease and Associated Disorders, 2013, 27, 153-156.	1.3	41
54	Inflammation and dementia: Using rheumatoid arthritis as a model to develop treatments?. Autoimmunity Reviews, 2018, 17, 919-925.	5.8	40

#	Article	IF	Citations
55	ABCA7 p.G215S as potential protective factor for Alzheimer's disease. Neurobiology of Aging, 2016, 46, 235.e1-235.e9.	3.1	37
56	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. Health Technology Assessment, 2017, 21, 1-192.	2.8	37
57	Microglial motility in Alzheimerâ€™s disease and after AÎ²42 immunotherapy: a human post-mortem study. Acta Neuropathologica Communications, 2019, 7, 174.	5.2	35
58	A Multi-Center Study of ACE and the Risk of Late-Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2011, 24, 587-597.	2.6	33
59	Imaging in dementia with Lewy bodies: a review. Nuclear Medicine Communications, 2007, 28, 511-519.	1.1	32
60	Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications. CNS Neuroscience and Therapeutics, 2012, 18, 64-76.	3.9	32
61	Limitations of the HMPAO SPECT appearances of occipital lobe perfusion in the differential diagnosis of dementia with Lewy bodies. Nuclear Medicine Communications, 2007, 28, 451-456.	1.1	31
62	Effect of active AÎ² immunotherapy on neurons in human Alzheimer's disease. Journal of Pathology, 2015, 235, 721-730.	4.5	31
63	Polygenic risk score in postmortem diagnosed sporadic early-onset Alzheimer's disease. Neurobiology of Aging, 2018, 62, 244.e1-244.e8.	3.1	30
64	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. Translational Psychiatry, 2020, 10, 267.	4.8	30
65	Inflammation in dementia with Lewy bodies. Neurobiology of Disease, 2022, 168, 105698.	4.4	26
66	Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimerâ€™s Disease: A Review. Frontiers in Human Neuroscience, 2022, 16, 866434.	2.0	25
67	Downregulated apoptosis and autophagy after antiâ€AÎ² immunotherapy in Alzheimer's disease. Brain Pathology, 2018, 28, 603-610.	4.1	24
68	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimerâ€™s disease. PLoS ONE, 2019, 14, e0218111.	2.5	23
69	The Camberwell Dementia Case Register. International Journal of Geriatric Psychiatry, 1996, 11, 369-375.	2.7	20
70	No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2011, 156, 764-771.	1.7	17
71	Effect of amyloidâ€Îβ (<scp>A</scp>Î²) immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase <scp>(GSK</scp>)â€3Î². Neuropathology and Applied Neurobiology, 2015, 41, 445-457.	3.2	17
72	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimerâ€™s disease: an observational clinical study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 1219-1226.	1.9	17

#	Article	IF	Citations
73	Impact of 123I-FP-CIT (DaTSCAN) SPECT on the diagnosis and management of patients with dementia with Lewy bodies. Nuclear Medicine Communications, 2011, 32, 298-302.	1.1	15
74	The clinical phenotype of familial and sporadic late onset Alzheimer's disease. International Journal of Geriatric Psychiatry, 2002, 17, 146-149.	2.7	14
75	Reply to â€œSpecificity of mechanisms for plaque removal after AÎ² immunotherapy for Alzheimer diseaseâ€. Nature Medicine, 2004, 10, 118-119.	30.7	12
76	Dementia known to mental health services: First findings of a case register for a defined elderly population. International Journal of Geriatric Psychiatry, 1995, 10, 875-881.	2.7	10
77	Clinical involvement in anti-dementia drug trialsâ€”why bother?. International Journal of Geriatric Psychiatry, 1999, 14, 258-260.	2.7	3
78	Apolipoprotein E and Functional Illness in the Elderly. International Psychogeriatrics, 1998, 10, 3-6.	1.0	1
79	Common infections and increased risk of developing dementia: compelling evidence for intervention studies. The Lancet Healthy Longevity, 2021, , .	4.6	1
80	The Molecular Pathology of Severe Dementia. , 2006, , 33-40.		0
81	The Role of Adaptive and Innate Immunity in Alzheimerâ€™s Disease. , 2021, , 213-232.		0